×

Eighteen New Verigene Clinical and Economic Studies Presented at CVS, ECCMID and MAD-ID 2015

NORTHBROOK, Ill., May 27, 2015 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that 18 studies performed by various U.S. and international hospitals were recently presented at the annual Clinical Virology Symposium (CVS) in Daytona Beach, Florida, the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, and the Making a Difference in Infectious Diseases (MAD-ID) Conference in Orlando, Florida.

The 18 studies presented at these meetings utilized five different Verigene® multiplex infectious disease tests: Verigene Gram-Positive Blood Culture (BC-GP), Gram-Negative Blood Culture (BC-GN), Enteric Pathogens (EP), Respiratory Virus Plus (RV+), and Respiratory Pathogens Flex™ IUO (RP Flex™) Tests. By highlighting the positive impact of rapid diagnostics on patient outcomes, antimicrobial stewardship efforts, healthcare costs and infection control efforts, these studies collectively illustrate the wide range of potential benefits the Verigene test menu can provide to multiple stakeholders throughout the hospital.

"The data presented at these conferences further demonstrates the accuracy, reliability, and clinical and economic value of our menu of multiplex molecular tests," said Michael McGarrity, Nanosphere's president and chief executive officer. "In this era of growing antibiotic resistance, we feel Nanosphere's broad menu serves as a vital tool for healthcare providers in their efforts to control the spread of resistance."

Following are selected studies presented during CVS 2015, ECCMID 2015 and MAD-ID 2015:

CVS 2015 (Full abstracts can be found at www.clinicalvirologysymposium.org)

"Evaluation of the Verigene RP Flex Investigational Use Only Test for Detecting Viral and Bacterial Respiratory Pathogens in Nasopharyngeal and Simulated Specimens," P. Granato, Laboratory Alliance of Central New York. (Abstract)

"Diagnostic Performance of the Investigational Use Only (IUO) Nanosphere RP Flex, A Highly Multiplexed Respiratory Pathogen Nucleic Acid Detection Test," J. Miller, Johns Hopkins Hospital. (Abstract)

ECCMID 2015 (Full abstracts can be found at www.eccmid.org)

"Use of the Nanosphere Verigene Gram-Negative Blood Culture (BC-GN) System for More Rapid Bacterial Identification and Antimicrobial Optimization in Patients with Gram-Negative Rod Bacteremia," T. Bias, Hahnemann University Hospital. (Abstract)

"Outcomes Utilizing Rapid Diagnostics Technology (RDT) Coupled with Pharmacist Intervention in Patients with Gram-Positive Bloodstream Infections (BSI)," S. Revolinkski, Froedtert Hospital and Medical College of Wisconsin. (Abstract)

MAD-ID 2015

"Results of Rapid Identification of Gram-Positive Bacteria Combined with Rapid Pharmacy Notification and Treatment in a Community Hospital Healthcare System," K. McNabb, New Hanover Regional Medical Center.

"Outcomes from Implementation of Rapid Identification Test for Detection of Gram-Positive Bacteria and Resistance Factors into a Pharmacist-Directed Antimicrobial Stewardship Protocol," A. Heyerly, Lutheran Hospital of Indiana.

Additionally, new performance and clinical outcome data will be presented in seven studies at the 115th General Meeting of the American Society for Microbiology (asm2015), to be held in New Orleans, Louisiana on May 30-June 2, 2015.

About the Verigene® System

The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the bloodstream, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

CONTACT: Investors: Ann Wallin Interim Chief Financial Officer Nanosphere, Inc. 847-400-9181 awallin@nanosphere.us Michael Rice Founding Partner LifeSci Advisors 646-597-6979 mrice@lifesciadvisors.com Media: Zachary Crowther Director of Marketing Nanosphere, Inc. 847-400-9074 zcrowther@nanosphere.us

Source:Nanosphere, Inc.